8-K: IRulya Therapeutics Relaunches, Reports Q3 Results, Eyes 2028 Cash Runway

IRulya Therapeutics Inc. announced its third quarter 2026 financial results, detailing a corporate relaunch, progress in its LAM-001 clinical programs, and a cash position expected to fund operations through 2028.

Summary

• IRulya Therapeutics Inc. (formerly Quince Therapeutics, Inc.) reported its third quarter 2026 financial results, coinciding with a corporate rebranding and relisting on the Nasdaq Capital Market under the ticker IRLA.
• The company's primary focus is on LAM-001, an inhaled rapamycin formulation for serious pulmonary diseases.
• Phase 2 data for LAM-001 in Bronchiolitis Obliterans Syndrome (BOS) post-lung transplant is anticipated in Q1 2027.
• Phase 2b data for LAM-001 in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) is expected in Q1 2028.
• A new Phase 2 study for LAM-001 in Sarcoidosis Associated Pulmonary Hypertension (SAPH) is planned for Q4 2026, with data expected in Q4 2028.
• As of September 30, 2026, the company held $105.2 million in cash, cash equivalents, and investments, which is projected to sustain operations through the end of 2028.
• The company reported a net loss of $27.7 million for Q3 2026, or $2.31 per share, compared to a net loss of $13.4 million, or $49.83 per share, in Q3 2025.
• Research and development expenses decreased to $5.9 million in Q3 2026 from $8.1 million in Q3 2025, primarily due to the wind-down of a previous program, though offset by increased LAM-001 study costs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic report, highlighting significant corporate restructuring and promising clinical trial timelines, balanced by substantial net losses and the inherent risks of drug development.

Positives

• Significant cash reserves of $105.2 million as of September 30, 2026, providing an estimated operational runway through the end of 2028.
• Successful corporate relaunch and rebranding as IRulya Therapeutics Inc., with common stock now trading on the Nasdaq Capital Market under the ticker IRLA.
• Key leadership appointments including a new CEO, CFO, and COO, along with the addition of new board members.
• LAM-001 development progressing across multiple clinical indications with defined timelines for data readouts.
• Phase 2 trial for LAM-001 in BOS is fully enrolled, with data expected in Q1 2027.
• Planned initiation of a Phase 2 study for LAM-001 in SAPH in Q4 2026.
• The company's focus on LAM-001, a potentially first-in-class inhaled rapamycin for serious pulmonary diseases, targeting the mTOR pathway.

Negatives

• Reported a substantial net loss of $27.7 million for the third quarter of 2026.
• Net loss per share was $2.31 for Q3 2026, a significant figure given the number of outstanding shares.
• General and administrative expenses increased significantly to $9.0 million in Q3 2026 from $3.3 million in Q3 2025, largely due to post-acquisition professional fees and personnel costs.
• The company has a history of significant net losses and net loss per share, even after accounting for reverse stock splits.

Risks

• Clinical trial results may not be indicative of future results, especially in larger populations.
• Potential safety and other complications related to LAM-001.
• The ability to obtain and maintain regulatory approval for LAM-001.
• Competition within the biopharmaceutical industry.
• The scope, progress, and expansion of LAM-001 development.
• Market acceptance of LAM-001 compared to alternative therapies.
• The company's ability to fund its operations and clinical development plans.
• General macroeconomic and geopolitical conditions impacting the business.

Future Outlook

The company anticipates its current cash position will fund operations through the end of 2028, enabling multiple Phase 2 clinical data readouts. Key upcoming milestones include the initiation of a Phase 2 study in SAPH in Q4 2026, and data readouts for BOS in Q1 2027 and PH-ILD in Q1 2028.

Management Comments

• "This has been a transformative quarter for our company as we relaunched with a new name and sharpened focus on LAM-001, a potentially first in class inhaled formulation of rapamycin for serious pulmonary diseases," said Brigette Roberts, M.D., Chief Executive Officer of IRulya Therapeutics.
• "By targeting the mTOR pathway directly in the lungs, LAM-001 holds promise as a potentially disease modifying intervention designed to simultaneously minimize systemic exposure and side effects in these conditions."
• "With a cash runway sufficient to deliver Phase 2 clinical results from multiple indications, we believe IRulya is in a great position to realize LAM-001s potential."

Industry Context

StockSavvy.ai notes that IRulya Therapeutics' relaunch and focus on LAM-001 align with the biopharmaceutical industry's ongoing pursuit of targeted therapies for rare and underserved pulmonary conditions. The company's strategy leverages rapamycin's known mTOR pathway inhibition, a mechanism being explored across various therapeutic areas. The company's cash runway projection through 2028 is a critical factor for clinical-stage biotechs, allowing for the progression of multiple drug candidates.

Comparison to Industry Standards

• The projected cash runway through 2028 for a clinical-stage biopharmaceutical company is generally considered strong, providing ample time for clinical development and data readouts.
• The net loss of $27.7 million in Q3 2026 is substantial but not uncommon for companies in the clinical development phase, especially those undergoing significant restructuring or initiating new trials.
• The increase in G&A expenses due to post-acquisition professional fees is a typical, albeit temporary, cost associated with significant corporate events like name changes and potential restructuring.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The rebranding and relisting on Nasdaq may impact investor perception and liquidity. The substantial net loss and future clinical trial data are key factors for shareholder value.
• Employees: Appointment of new leadership and potential severance/retention bonuses mentioned in G&A expenses suggest internal organizational changes.
• Creditors: The company's cash position and projected runway are positive indicators for its ability to meet financial obligations.

Next Steps

• Initiate Phase 2 study of LAM-001 in SAPH in Q4 2026.
• Anticipate Phase 2 data readout for LAM-001 in BOS in Q1 2027.
• Anticipate Phase 2b data readout for LAM-001 in PH-ILD in Q1 2028.
• Anticipate Phase 2 data readout for LAM-001 in SAPH in Q4 2028.

Key Dates

Recommendation

The company has undergone a significant transformation with a new name, ticker, and leadership, focusing on a promising drug candidate (LAM-001) with clear clinical development timelines. The strong cash position provides a substantial runway. However, the significant net losses and the inherent risks associated with clinical-stage biopharmaceutical development warrant a 'hold' recommendation until further clinical data de-risks the program and demonstrates clear progress towards commercialization.

Keywords

IRulya Therapeutics, LAM-001, rapamycin, pulmonary diseases, Bronchiolitis Obliterans Syndrome, Pulmonary Hypertension, Interstitial Lung Disease, Sarcoidosis